Within the "MH/SUD Parity Rule Division 2 Data Collection Reporting Form" template, in the worksheet titled "Claims and Utilization Review," for medical/surgical, MH/SUD, and for each of the classifications listed in § 21.2425(c) of this title (relating to Claims and Utilization Review: Reporting Classifications), an issuer must provide the following aggregate claims and utilization review data for the reporting year:
(1) the number of reported claims for services or benefits that have been provided: (B) by out-of-network providers that were covered as in-network benefits;(D) that were administratively denied; and(E) that were adversely determined;(2) the number of utilization reviews, including:(A) preauthorization requests for: (i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(B) preauthorization requests approved for: (i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(C) preauthorization requests that received a peer-to-peer or physician-to-physician review for: (i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(D) preauthorization requests that were subject to a fail-first or step therapy requirement;(E) preauthorization requests that were adversely determined for:(i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(F) concurrent reviews for: (i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(G) concurrent reviews approved for: (i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(H) concurrent reviews that received a peer-to-peer or physician-to-physician review for: (i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(I) concurrent reviews that were adversely determinedfor:(i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(J) retrospective reviews for: (i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(K) retrospective reviews that were approved for:(i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(L) retrospective reviews that received a peer-to-peer or physician-to-physician review for: (i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(M) retrospective reviews that were adversely determined for:(i) children ages 0 - 12;(ii) adolescents ages 13 - 17; and(3) the number of adverse determinations that were internally appealed that: (A) then received a peer-to-peer or physician-to-physician review on internal appeal;(B) were again adversely determined on internal appeal; and(C) were reversed on internal appeal; and(4) the number of adverse determinations independently reviewed that were:(A) upheld on independent review; and(B) reversed on independent review.28 Tex. Admin. Code § 21.2426
Adopted by Texas Register, Volume 46, Number 36, September 3, 2021, TexReg 5584, eff. 9/7/2021